Long-term effectiveness of ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy

Brain and Development

Volumn 34, Issue 5, 2012, Pages 344-348

  Hwang, Hee ^a,b   Kim, Hunmin ^a,c   Kim, Seung Hyo ^a,b   Kim, Se Hee ^a,c   Lim, Byung Chan ^a,c   Chae, Jong Hee ^a,c   Choi, Ji Eun ^a   Kim, Ki Joong ^a,c   Hwang, Yong Seung ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University Children's Hospital   (South Korea)

Author keywords

Childhood absence epilepsy; Effectiveness; Ethosuximide; Lamotrigine; Valproic acid

Indexed keywords

ETHOSUXIMIDE; LAMOTRIGINE; VALPROIC ACID;

ABDOMINAL PAIN; ABSENCE; ALOPECIA; ANTICONVULSANT THERAPY; ARTICLE; CHILD; CHILDHOOD ABSENCE EPILEPSY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DISEASE FREE SURVIVAL; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL RECORD REVIEW; NAUSEA AND VOMITING; PRESCHOOL CHILD; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; WEIGHT GAIN;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; ELECTROENCEPHALOGRAPHY; EPILEPSY, ABSENCE; ETHOSUXIMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZINES; VALPROIC ACID; YOUNG ADULT;

EID: 84859911848     PISSN: 03877604     EISSN: 18727131     Source Type: Journal    
DOI: 10.1016/j.braindev.2011.08.007     Document Type: Article

References (21)

1. Jallon P., Loiseau P., Loiseau J. Newly diagnosed unprovoked epileptic seizures: presentation at diagnosis in CAROLE study. Coordination Active du Réseau Observatoire Longitudinal de l' Epilepsie. Epilepsia 2001, 42:464-475.
2. Berg A.T., Shinnar S., Levy S.R., Testa F.M., Smith-Rapaport S., Beckerman B. How well can epilepsy syndromes be identified at diagnosis? A reassessment 2 years after initial diagnosis. Epilepsia 2000, 41:1269-1275.
3. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989, 30:389-399. Commission on Classification and Terminology of the International League Against Epilepsy.
4. Duchowny M., Harvey A.S. Pediatric epilepsy syndromes: an update and critical review. Epilepsia 1996, 37:S26-S40.
5. Posner E., Mohamed K., Marson A. A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine. Seizure 2005, 14:117-122.
6. Callaghan N., O'Hare J., O'Driscoll D., O'Neill B., Daly M. Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev Med Child Neurol 1982, 24:830-836.
7. Sato S., White B.G., Penry J.K., Dreifuss F.E., Sackellares J.C., Kupferberg H.J. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982, 32:157-163.
8. Glauser T., Cnaan A., Shinnar S., Hirtz D., Dlugos D., Masur D., et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010, 362:790-799.
9. Loiseau J, Panayiotopoulos P. Childhood absence epilepsy [Internet]. 2000. Available from: [updated 2002 November 5; cited 2010 December 2]. http://www.ilae-epilepsy.org/ctf/childhood_absence.html.
10. Ma X., Zhang Y., Yang Z., Liu X., Sun H., Qin J., et al. Childhood absence epilepsy: elctroclinical features and diagnostic criteria. Brain Dev 2011, 33:1144-1149.
11. Sadleir L.G., Farrell K., Smith S., Connolly M.B., Scheffer I.E. Electroclinical features of absence seizures in childhood absence epilepsy. Neurology 2006, 67:413-418.
12. Grosso S., Galimberti D., Vezzosi P., Farnetani M., Di Bartolo R., Bazzotti S., et al. Childhood absence epilepsy: evolution and prognostic factors. Epilepsia 2005, 46:1796-1801.
13. Coppola G., Auricchio G., Federico R., Carotenuto M., Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia 2004, 45:1049-1053.
14. Camfield C., Camfield P. Management guidelines for children with idiopathic generalized epilepsy. Epilepsia 2005, 46:112-116.
15. Callenbach P.M.C., Bouma P.A.D., Geerts A., Arts W.F.M., Stroink H., Peeters E.A.J., et al. Long-term outcome of childhood absence epilepsy: dutch study of epilepsy in childhood. Epilepsy Res 2009, 83:249-256.
16. Frank L.M., Enlow T., Holmes G., Manasco P., Concannon S., Chen C., et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999, 41:357-359.
17. Glauser T., Ben-Menachem E., Bourgeois B., Cnaan A., Chadwick D., Guerreiro C., et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006, 47:1094-1120.
18. Bilo L., Meo R. Polycystic ovary syndrome in women using valproate: a review. Gynecol Endocrinol 2008, 24:562-570.
19. Coppola G., Licciardi F., Sciscio N., Russo F., Carotenuto M., Pascotto A. Lamotrigine as first-line drug in childhood absence epilepsy: a clinical and neurophysiological study. Brain Dev 2004, 26:26-29.
20. Holmes G., Frank L.M., Sheth R., Philbrook B., Wooten J., Vuong A., et al. Lamotrigine monotherapy for newly diagnosed typical absence seizures in children. Epilepsy Res 2008, 82:124-132.
21. Panayiotopoulos C.P. Treatment of typical absence seizures and related epileptic syndromes. Paediatr Drugs 2001, 3:379-403.